Outils & Documentation

Nos publications

Depuis sa création, l’Institut Roche a mis son expertise au profit de nombreuses publications scientifiques.

HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. Oncotarget, 5(16), 7138–7148.

Thomas, G., Chardès, T., Gaborit, N., Mollevi, C., Leconet, W., Robert, B., Radosevic-Robin, N., Penault-Llorca, F., Gongora, C., Colombo, P. E., Lazrek, Y., Bras-Goncalves, R., Savina, A., Azria, D., Bazin, H., Pèlegrin, A., & Larbouret, C. (2014).

https://doi.org/10.18632/oncotarget.2231
Voir plus

A cancer model for the angiogenic switch. Journal of theoretical biology, 360, 21–33.

Viger, L., Denis, F., Rosalie, M., & Letellier, C. (2014).

https://doi.org/10.1016/j.jtbi.2014.06.020
Voir plus

Phosphoantigens and butyrophilin 3A1 induce similar intracellular activation signaling in human TCRVγ9+ γδ T lymphocytes. Immunology letters, 161(1), 133–137.

Decaup, E., Duault, C., Bezombes, C., Poupot, M., Savina, A., Olive, D., & Fournié, J. J. (2014).

https://doi.org/10.1016/j.imlet.2014.05.011
Voir plus

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia, 28(12), 2367–2375.

Rossille, D., Gressier, M., Damotte, D., Maucort-Boulch, D., Pangault, C., Semana, G., Le Gouill, S., Haioun, C., Tarte, K., Lamy, T., Milpied, N., Fest, T., Groupe Ouest-Est des Leucémies et Autres Maladies du Sang, & Groupe Ouest-Est des Leucémies et Autres Maladies du Sang (2014).

https://doi.org/10.1038/leu.2014.137
Voir plus

Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings. BMC cancer, 14, 178.

Bieche, I., Vacher, S., Vallerand, D., Richon, S., Hatem, R., De Plater, L., Dahmani, A., Némati, F., Angevin, E., Marangoni, E., Roman-Roman, S., Decaudin, D., & Dangles-Marie, V. (2014).

https://doi.org/10.1186/1471-2407-14-178
Voir plus

Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO network. Gynecologic oncology, 132(1), 181–187.

Maillet, D., Goulvent, T., Rimokh, R., Vacher-Lavenu, M. C., Pautier, P., Alexandre, J., Pujade-Laurraine, E., Devouassoux-Shisheboran, M., Treilleux, I., Ray-Coquard, I., & Savina, A. (2014).

https://doi.org/10.1016/j.ygyno.2013.10.013
Voir plus

Cell growth in aggregates determines gene expression, proliferation, survival, chemoresistance, and sensitivity to immune effectors in follicular lymphoma. The American journal of pathology, 184(1), 282–295.

Gravelle, P., Jean, C., Familiades, J., Decaup, E., Blanc, A., Bezombes-Cagnac, C., Laurent, C., Savina, A., Fournié, J. J., & Laurent, G. (2014).

https://doi.org/10.1016/j.ajpath.2013.09.018
Voir plus

Mitochondrial oxidative stress is the Achille’s heel of melanoma cells resistant to Braf-mutant inhibitor. Oncotarget, 4(11), 1986–1998.

Corazao-Rozas, P., Guerreschi, P., Jendoubi, M., André, F., Jonneaux, A., Scalbert, C., Garçon, G., Malet-Martino, M., Balayssac, S., Rocchi, S., Savina, A., Formstecher, P., Mortier, L., Kluza, J., & Marchetti, P. (2013).

https://doi.org/10.18632/oncotarget.1420
Voir plus

Prediction of Shrinkage of Individual Parameters Using the Bayesian Information Matrix in Non-Linear Mixed Effect Models with Evaluation in Pharmacokinetics. Pharm Res 30, 2355–2367 (2013).

Combes, F.P., Retout, S., Frey, N. et al.

https://doi.org/10.1007/s11095-013-1079-3
Voir plus
Plus de résultats :

Résultats :99/110